Stock Price Forecast

March 14, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading INmune Bio Inc chart...

About the Company

inmune bio inc. is a clinical stage immuno-oncology company focused on harnessing the patient’s immune system to treat cancer. inkmune, the company’s lead product, primes patient’s nk cells (natural killer cells) to kill cancer. inmune is targeting residual disease, the cancer cells that survive initial treatments that return to cause the cancer relapse. by controlling residual disease, patients may live longer. using a novel mechanism of action and a precision medicine approach, inkmune therapy should enhance nk cells’ ability to eliminate residual disease.

Exchange

NASDAQ

Website

inmunebio.com

$0M

Total Revenue

14

Employees

$205M

Market Capitalization

-6.92

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $INMB News

INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy

5d ago, source:

INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announces its ...

Buy Rating Affirmed for Inmune Bio Amid Promising Alzheimer’s Treatment Developments

12d ago, source:

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Inmune Bio (INMB – Research Report), with a ...

INmune Bio Reports Significant EEG Improvement in Alzheimer’s Patients Treated with XPro™

13d ago, source:

Patients with Alzheimer’s Disease show improvement in brainwaves following 4 weeks of XPro™ therapy. Boca Raton, Florida, March 05, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: INMB) (the “Company”), a clinical ...

Assembly Bio to launch four infectious disease trials in 2024

13h ago, source: GlobalData on MSN

Assembly Bio has four candidates in its pipeline, one of which is being developed as part of a partnership with Gilead ...

Graphite Bio declares special $1.03 dividend

on MSN ago, source:

Graphite Bio (GRPH) declares $1.03/share special dividend. Payable March 21; for shareholders of record March 18; ex-div March 15. See GRPH Dividend Scorecard, ...

Allogene (ALLO) Inks Deal With Arbor Bio for CRISPR Technology

5d ago, source: Zacks.com on MSN

Allogene Therapeutics ALLO announced that it has entered into a non-exclusive licensing agreement with privately-held Arbor ...

Merus, Gilead ink $1.5B+ deal; Biomx merges with Adaptive Phage

12d ago, source: BioWorld

Though down nearly 6% in January, the BioWorld Drug Developers Index (BDDI) rebounded in February, finishing the month with a 4.41% increase and outperforming both the Nasdaq Biotechnology Index (NBI; ...

INmune Bio, Inc.: INmune Bio Reports Significant EEG Improvement in Alzheimer's Patients Treated with XPro

13d ago, source:

Patients with Alzheimer's Disease show improvement in brainwaves following 4 weeks of XPro therapy. Boca Raton, Florida, March 05, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...